TABLE 3.

Univariable Analysis of Factors Associated With the Development of AU on the First Postoperative Colonoscopy

	No. (%)	Odds Ratio (95% confidence interval)	P
Age	—	0.99 (0.97–1.01)	0.28
Male Gender	—	1.71 (0.94–3.11)	0.08
Disease Duration (years)	—	1.00 (0.98–1.01)	0.62
Internal Fistulas	96 (56.5)	0.94 (0.51–1.72)	0.83
Ileal Crohn’s Location	79 (44.6)	0.85 (0.63–1.15)	0.30
Perianal Disease	24 (14.1)	1.32 (0.55–3.18)	0.53
Postoperative Complication	26 (14.3)	1.56 (0.67–3.65)	0.31
Current Smoker	13 (7.9)	1.05 (0.34–3.27)	0.93
Diversion at ICR	9 (5.1)	0.45 (0.11–1.88)	0.28
Preoperative Abscess	41 (23.6)	0.86 (0.42–1.73)	0.67
Side to Side Anastomosis	120 (87.0)	0.63 (0.34–1.18)	0.15
Stapled Anastomosis	169 (92.9)	0.93 (0.30–2.89)	0.90
Biologic Use at Colonoscopy	98 (57.7)	0.73 (0.39–1.33)	0.30
TNF Use at Colonoscopy	91 (53.5)	0.64 (0.35–1.18)	0.15
IM Use at Colonoscopy	56 (32.9)	1.08 (0.57–2.04)	0.82
CT Use at Colonoscopy	28 (16.6)	0.64 (0.28–1.45)	0.29
Biologic Use Prior to ICR	73 (40.1)	0.90 (0.50–1.64)	0.74
Prior ICR	43 (23.6)	0.84 (0.42–1.66)	0.61
Time from ICR-Colonoscopy	—	1.00 (0.99–1.00)	0.10

Abbreviations: IM, immunomodulatory; CT, combination therapy.